Company: ENTXW
Filing Date: 2025-01-10
Form Type: 424B5
Source: 0001178913-25-000079
Chunk: 12

Company: Entera Bio Ltd.
Filing Date: 2025-01-10
Form: 424B5
Chunk 12
---
 patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products similar 
 or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected;                                                                                                                         |

| • | Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain; |

| • | Our reliance on third parties to conduct our clinical trials and on third-party suppliers to supply or produce our product candidates; |

| • | Our interpretation of FDA feedback and guidance and how such guidance may impact our clinical development plan; |

| • | Our ability to use and expand our drug delivery technology (“N-Tab™”) to additional product candidates; |

| • | Our operation as a development stage company with limited operating history and a history of operating losses and our ability to fund our operations going forward; |

| • | our expectations regarding licensing, business transactions and strategic collaborations, including our ongoing collaboration with Amgen; |

| • | Our competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories we pursue; |

| • | Our ability to establish and maintain development and commercialization collaborations; |

| • | Our ability to manufacture and supply enough material to support our clinical trials and any potential future commercial requirements; |

| • | The size of any market we may target and the adoption of our product candidates, if approved, by physicians and patients; |

| • | Our ability to obtain, maintain and protect our intellectual property and operate our business without infringing, misappropriating, or otherwise violating any intellectual property rights of others; |

| • | Our ability to retain key personnel and recruit additional qualified personnel; |

| • | Our ability to comply with laws and regulations that currently apply or become applicable to our business in Israel, the United States and internationally; |

| • | Our ability to manage growth; and |

| • | The duration and intensity of the ongoing Israel-Hamas War, and escalation of Hezbollah's conflict since October 2023 as well as the developing conflict with Iran and its proxies in the Middle East, such as the Houthis in Yemen and 
 militias in Iraq and Syria, and their impact on our operations and workforce, including our research and development and clinical trials.                                                                                               |

All forward-looking statements